RLAY Reports $642M Cash, FDA BTD for Zovegalisib in Breast Cancer, Phase 3 1L Trial 2027, RLY-8161 NRAS Trial Initiated
Relay Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $14.05
-1.8% in 3d after detection
Post-detection moves
1h
—
1d
-0.6%
3d
-1.8%
7d
-1.7%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS